The State of Men's Health Act aims to address rising health risks and premature death among men by establishing a new Office of Men's Health within the Department of Health and Human Services. Before creating this office, the bill requires the Government Accountability Office to conduct a study on men's health disparities and recommend ways to improve federal coordination and awareness. Once established, the new office will coordinate screening programs for conditions like prostate cancer and diabetes, maintain a database of best practices, and report its findings to Congress. The legislation does not authorize new funding, meaning the office must operate using existing budget resources.
The Preventing Forced Abortions Act of 2026 prohibits federal courts from enforcing any part of a surrogacy agreement that forces a surrogate mother to have an abortion. Instead, the law mandates that courts must uphold the financial compensation promised to the surrogate, even if the contract includes penalties or reduced payments for refusing an abortion. This legislation grants federal district courts specific authority to hear civil cases involving surrogacy contracts and defines key terms such as "abortion" and "surrogate mother" to clarify the scope of the protections.
The Connected Vehicle Security Act of 2026 restricts the importation, sale, and use of connected vehicles and related technology from China, Russia, Iran, and North Korea to protect national security. Starting in 2027, the bill generally bans these vehicles if they originate from or are controlled by these countries, with separate restrictions on software and hardware taking effect in 2030. The Secretary of Commerce is authorized to issue specific exemptions for items that do not pose a security risk and must publish a list of approved products. The law also requires companies to submit declarations confirming their vehicles comply with the rules and imposes heavy fines for violations.
The Aviation Innovation and Global Competitiveness Act requires the Federal Aviation Administration (FAA) to improve transparency and predictability in certifying new aircraft and technologies. It directs the FAA to publish a plan within 180 days to streamline handling technical issues during certification, set standard timelines for key steps (like applicant responses), and convert stable issues into published policies. The bill also mandates updated guidance on delegating certification tasks to ensure safety and efficiency, especially for emerging sectors like advanced air mobility. The FAA must consult with industry stakeholders and report annually to Congress on implementation progress.
This bill requires pharmacy benefits managers (PBMs) administering prescription drug benefits for federal employee health plans to reimburse pharmacies at specific rates, including the national average drug cost plus a small percentage or $50, whichever is lower. It prohibits PBMs from favoring their own pharmacies, restricting patient choice, or reducing pharmacy payments after claims are processed. The bill establishes $10,000 civil penalties for violations, with debarment from federal health plans after 10 penalties in 10 years. This directly affects PBMs, in-network pharmacies, and federal health benefit plans covering millions of federal employees and their families. The law aims to ensure fair reimbursement practices and maintain pharmacy choice under the Federal Employees Health Benefits Program.
The Women's Business Centers Improvement Act of 2026 updates the Small Business Administration's Women's Business Center Program by establishing a new Office of Women's Business Ownership and defining specific rules for how these centers are funded and operated. The bill allows eligible organizations, such as nonprofits and state economic development groups, to receive up to $300,000 annually in grants to provide counseling and training on business formation, finance, and marketing specifically for women entrepreneurs. To receive these funds, organizations must secure matching contributions from non-federal sources, undergo regular financial and programmatic reviews, and adhere to new accreditation standards that will be implemented within 270 days of the bill's enactment. Additionally, the legislation mandates an annual report detailing the number of participants, jobs created, and capital secured by the centers to ensure transparency and measure program effectiveness.
The MARA Act of 2026 establishes a new Office of Aquaculture within the National Oceanic and Atmospheric Administration to oversee and promote commercial-scale offshore aquaculture projects in U.S. waters. This new office will coordinate with other federal agencies to streamline the permitting process, develop best management practices based on scientific data, and provide technical assistance and grants to industry stakeholders. The bill authorizes the issuance of permits for demonstration projects that must use native species, minimize environmental risks, and prioritize the safety of existing fishing and navigation activities. Additionally, the legislation mandates two major studies: one by the National Academies to evaluate the scientific basis for regulating offshore aquaculture and another by the Government Accountability Office to assess the economic and regulatory viability of the industry over time.
This bill, known as the ABLE MATCH Act, aims to help individuals with disabilities save money by providing a federal tax credit that is automatically deposited into their ABLE savings accounts. The program targets low-income earners by offering a 100% match on up to $2,000 of annual contributions, provided their income falls below 200% of the federal poverty limit, with the credit amount gradually decreasing for higher incomes. To support wider adoption, the legislation also authorizes the Treasury to award $5 million annually in grants to states for promoting these accounts and includes a requirement for collecting demographic data on account holders. These changes are designed to increase financial security for people with disabilities by encouraging savings without jeopardizing their eligibility for other government benefits.
This bill, known as the STOP Nitazenes Act, directs the federal government to permanently classify nitazenes and related synthetic opioids as Schedule I controlled substances, placing them in the same legal category as heroin and fentanyl. The legislation specifically targets a broad range of chemical compounds, including etonitazene and other variants, by defining them as 2-benzylbenzimidazole opioids and requiring the Attorney General to publish a list of qualifying substances. Under the bill, any nitazene substance temporarily scheduled under emergency provisions would be made permanently scheduled upon enactment, ensuring long-term federal control. The law also mandates that the Attorney General issue implementing rules within one year, allowing for immediate interim enforcement while providing opportunities for public comment before final regulations are established.
The AADAPT Act reauthorizes and expands Project ECHO grants to improve Alzheimer’s and dementia care through technology-enabled training. It specifically funds grants for healthcare providers in rural, frontier, or medically underserved areas to enhance early diagnosis, quality care, and provider retention for dementia patients. The bill authorizes $1 million annually (2027-2032) for these dementia-focused training programs, requiring funds to supplement - not replace - existing resources. This directly supports primary care providers licensed to serve underserved communities, using collaborative online learning to address care gaps.
HR 2004, titled "Tyler’s Law," requires the Secretary of Health and Human Services to study how often hospital emergency departments test for fentanyl during overdose cases (beyond standard drug tests), including associated costs, patient benefits/risks, and impacts on privacy and patient-physician relationships. The study must be completed within one year of the bill's enactment. Based on the study results, the Secretary must issue guidance within six months on whether emergency departments should routinely test for fentanyl, how to inform clinicians about test contents, and how such testing may affect future overdose risks and health outcomes. This bill directly affects hospital emergency departments and patients experiencing overdoses by shaping future testing protocols.
HR 1266, the Combating Illicit Xylazine Act, adds xylazine - a veterinary sedative increasingly found in illicit drug mixtures - to Schedule III of the Controlled Substances Act, regulating its use and trafficking. It directly affects veterinarians, animal owners, and manufacturers by allowing xylazine to be legally dispensed for animal use under specific veterinary prescriptions, while prohibiting non-veterinary human use. The bill includes transition periods (60 days for practitioners, 1 year for labeling) to ease compliance for manufacturers and practitioners, and requires the DEA and FDA to expedite necessary applications. It also mandates two congressional reports on xylazine's illicit use and trafficking patterns, and directs the Sentencing Commission to review penalties for offenses involving xylazine.
